Published in Arch Dermatol Res on January 01, 1994
Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis. Cancer Res (2009) 1.18
Engraftment of precursor lesions of human cutaneous neoplasms onto C.B-17 SCID mice: a useful in vivo experimental model of carcinogenesis in human skin. Arch Dermatol Res (1995) 0.78
Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem (1981) 38.93
Studies on antibody production. I. A method for the histochemical demonstration of specific antibody and its application to a study of the hyperimmune rabbit. J Exp Med (1955) 16.36
A severe combined immunodeficiency mutation in the mouse. Nature (1983) 13.99
The isolation and characterization of the human suppressor inducer T cell subset. J Immunol (1985) 6.69
Laminin receptor on platelets is the integrin VLA-6. Nature (1988) 4.91
Regulated expression and binding of three VLA (beta 1) integrin receptors on T cells. Nature (1990) 4.66
The role of integrins alpha 2 beta 1 and alpha 3 beta 1 in cell-cell and cell-substrate adhesion of human epidermal cells. J Cell Biol (1990) 3.82
Epiligrin, a new cell adhesion ligand for integrin alpha 3 beta 1 in epithelial basement membranes. Cell (1991) 3.55
Evidence of functional lymphocytes in some (leaky) scid mice. J Exp Med (1988) 3.09
Integrin alpha 6/beta 4 complex is located in hemidesmosomes, suggesting a major role in epidermal cell-basement membrane adhesion. J Cell Biol (1991) 2.88
Novel function for beta 1 integrins in keratinocyte cell-cell interactions. J Cell Biol (1990) 2.39
Integrin alpha 2 beta 1 is upregulated in fibroblasts and highly aggressive melanoma cells in three-dimensional collagen lattices and mediates the reorganization of collagen I fibrils. J Cell Biol (1991) 2.08
Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1984) 2.02
The primary structure of the VLA-2/collagen receptor alpha 2 subunit (platelet GPIa): homology to other integrins and the presence of a possible collagen-binding domain. J Cell Biol (1989) 2.02
The integrin alpha 6 beta 4 is a laminin receptor. J Cell Biol (1992) 1.77
Integrin VLA-3: ultrastructural localization at cell-cell contact sites of human cell cultures. J Cell Biol (1989) 1.72
Expression of beta 1, beta 3, beta 4, and beta 5 integrins by human epidermal keratinocytes and non-differentiating keratinocytes. J Cell Biol (1991) 1.42
Recessive dystrophic epidermolysis bullosa phenotype is preserved in xenografts using SCID mice: development of an experimental in vivo model. J Invest Dermatol (1992) 1.20
Integrins of normal human epidermis: differential expression, synthesis and molecular structure. Br J Dermatol (1990) 1.20
Human vascular endothelial cells express a membrane protein complex immunochemically indistinguishable from the platelet VLA-2 (glycoprotein Ia-IIa) complex. Blood (1989) 1.16
Changes in cell surface glycoprotein expression during differentiation of human keratinocytes. J Invest Dermatol (1987) 1.12
Integrin receptors and RGD sequences in human keratinocyte migration: unique anti-migratory function of alpha 3 beta 1 epiligrin receptor. J Invest Dermatol (1992) 1.08
Membrane-associated glycoprotein (gp 160) identified on human lung tumors by a monoclonal antibody. Cancer Res (1986) 1.07
Establishment of a human cutaneous T-cell lymphoma in C.B-17 SCID mice. J Invest Dermatol (1990) 1.05
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1984) 1.05
Adhesion molecule mapping in normal human skin. Arch Dermatol Res (1989) 1.04
Expression of HLA antigens by human thymic epithelial cells. Hum Immunol (1982) 1.01
Expression of beta 1 integrins in normal human keratinocytes. Am J Med Sci (1991) 0.84
Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother (2001) 16.97
Interleukin-10 therapy--review of a new approach. Pharmacol Rev (2003) 3.51
Cooperation of a ubiquitin domain protein and an E3 ubiquitin ligase during chaperone/proteasome coupling. Curr Biol (2001) 3.21
Correlative light-electron microscopy reveals the tubular-saccular ultrastructure of carriers operating between Golgi apparatus and plasma membrane. J Cell Biol (2000) 2.79
Migration of highly aggressive MV3 melanoma cells in 3-dimensional collagen lattices results in local matrix reorganization and shedding of alpha2 and beta1 integrins and CD44. Cancer Res (1997) 2.26
A single laser method for subtraction of cell autofluorescence in flow cytometry. Cytometry (1987) 1.97
Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun (2009) 1.81
Klebsiella pneumoniae lipopolysaccharide O typing: revision of prototype strains and O-group distribution among clinical isolates from different sources and countries. J Clin Microbiol (1999) 1.75
Morphological characterization of a cell population responsible for natural killer activity. Immunology (1981) 1.73
Integrin VLA-3: ultrastructural localization at cell-cell contact sites of human cell cultures. J Cell Biol (1989) 1.72
Penetration of titanium dioxide microparticles in a sunscreen formulation into the horny layer and the follicular orifice. Skin Pharmacol Appl Skin Physiol (1999) 1.67
Detection of early micrometastases in subcutaneous fat of primary malignant melanoma patients by identification of tyrosinase-mRNA. Eur J Cancer (1996) 1.59
Organization of the monocyte/macrophage system of normal human skin. J Invest Dermatol (1990) 1.58
Analysis of V(H)-D-J(H) gene transcripts in B cells infiltrating the salivary glands and lymph node tissues of patients with Sjögren's syndrome. Arthritis Rheum (1999) 1.56
Human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer (1998) 1.56
Is there an interaction between interleukin-10 and interleukin-22? Genes Immun (2005) 1.54
Polyclonal expansion of T cells with the TCR V beta type of the tumour cell in lesions of cutaneous T-cell lymphoma: evidence for possible superantigen involvement. Br J Dermatol (2004) 1.53
New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis (2005) 1.47
Demonstration of frequent occurrence of clonal T cells in the peripheral blood but not in the skin of patients with small plaque parapsoriasis. Blood (1999) 1.47
Hypocomplementaemic urticarial vasculitis: successful treatment with cyclophosphamide-dexamethasone pulse therapy. Br J Dermatol (1998) 1.47
Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res (1999) 1.46
Identification of common dermatophytes (Trichophyton, Microsporum, Epidermophyton) using polymerase chain reactions. Br J Dermatol (1998) 1.44
Basal-cell adhesion molecule (B-CAM) is induced in epithelial skin tumors and inflammatory epidermis, and is expressed at cell-cell and cell-substrate contact sites. J Invest Dermatol (2000) 1.44
The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. J Immunol (1990) 1.44
T-cell receptor and immunoglobulin gene rearrangements in cutaneous T-cell-rich pseudolymphomas. J Invest Dermatol (1990) 1.43
A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol (2007) 1.42
IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest (1998) 1.40
Verrucosis of hands and feet in a patient with combined immune deficiency. J Am Acad Dermatol (1997) 1.39
Molecular cloning and functional characterization of brefeldin A-ADP-ribosylated substrate. A novel protein involved in the maintenance of the Golgi structure. J Biol Chem (1999) 1.39
Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-alpha. Mol Endocrinol (2000) 1.38
Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas. Int J Cancer (1995) 1.35
Functional hierarchy of simultaneously expressed adhesion receptors: integrin alpha2beta1 but not CD44 mediates MV3 melanoma cell migration and matrix reorganization within three-dimensional hyaluronan-containing collagen matrices. Mol Biol Cell (1999) 1.33
Epidermal growth factor-like repeats mediate lateral and reciprocal interactions of Ep-CAM molecules in homophilic adhesions. Mol Cell Biol (2001) 1.32
Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol (2009) 1.28
Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol (2007) 1.28
Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol (2005) 1.25
A continuous T-cell line from a patient with Sézary syndrome. Arch Dermatol Res (1987) 1.23
Note: stacked rings for terahertz wave-guiding. Rev Sci Instrum (2011) 1.22
Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol (2007) 1.21
Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene (2012) 1.20
Sclerotherapy for treatment of hemangiomas. Dermatol Surg (2000) 1.19
Candida africana sp. nov., a new human pathogen or a variant of Candida albicans? Mycoses (2001) 1.14
The Trop-2 signalling network in cancer growth. Oncogene (2012) 1.14
Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J Biol Chem (1999) 1.13
Cloning of the murine TROP2 gene: conservation of a PIP2-binding sequence in the cytoplasmic domain of TROP-2. Int J Cancer (1998) 1.13
Hair follicles--an efficient storage and penetration pathway for topically applied substances. Summary of recent results obtained at the Center of Experimental and Applied Cutaneous Physiology, Charité -Universitätsmedizin Berlin, Germany. Skin Pharmacol Physiol (2008) 1.12
Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene (2006) 1.12
Sunscreen application at the beach. J Cosmet Dermatol (2004) 1.12
Oligonucleotide typing reveals association of type I psoriasis with the HLA-DRB1*0701/2, -DQA1*0201, -DQB1*0303 extended haplotype. J Invest Dermatol (1993) 1.12
Migration of highly aggressive melanoma cells on hyaluronic acid is associated with functional changes, increased turnover and shedding of CD44 receptors. J Cell Sci (1996) 1.11
CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol (2006) 1.10
Influence of monomethylfumarate on monocytic cytokine formation--explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res (1997) 1.09
Effects of in vivo treatments with cyclosporin-A on mouse cell-mediated immune responses. Int J Immunopharmacol (1981) 1.08
Peripheral blood T cell clonality in mycosis fungoides -an independent prognostic marker? J Invest Dermatol (2000) 1.08
Contact urticaria and dermatitis from self-adhesive pads. Contact Dermatitis (1985) 1.08
Biochemical characterization of Trop-2, a cell surface molecule expressed by human carcinomas: formal proof that the monoclonal antibodies T16 and MOv-16 recognize Trop-2. Hybridoma (1992) 1.07
Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res (2000) 1.05
Case report. Osteomyelitis caused by high resistant Candida guilliermondii. Mycoses (1999) 1.04
Adhesion molecule mapping in normal human skin. Arch Dermatol Res (1989) 1.04
The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol (2003) 1.04
Distribution of bacteria in the epidermal layers and hair follicles of the human skin. Skin Pharmacol Physiol (2011) 1.03
Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization. Cytogenet Cell Genet (2001) 1.02
Online lectures for students in dermatology: a replacement for traditional teaching or a valuable addition? J Eur Acad Dermatol Venereol (2009) 1.01
A family study of atopic dermatitis. Clinical and genetic characteristics of 188 patients and 2,151 family members. Arch Dermatol Res (1990) 1.01
Increase of Enterobacter in neonatal sepsis: a twenty-two-year study. Pediatr Infect Dis J (2001) 1.01
Very low monocytic HLA-DR expression indicates high risk of infection--immunomonitoring for patients after neurosurgery and patients during high dose steroid therapy. Eur J Emerg Med (1995) 1.00
Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol (1996) 1.00
Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. J Clin Oncol (2000) 1.00
Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. Br J Dermatol (2003) 0.99
Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome. Leukemia (2011) 0.99
Human mast cells augment fibroblast proliferation by heterotypic cell-cell adhesion and action of IL-4. J Immunol (1998) 0.99
Reflectance confocal microscopy for noninvasive monitoring of therapy and detection of subclinical actinic keratoses. Dermatology (2009) 0.99
Mycetoma due to Exophiala jeanselmei and Mycobacterium chelonae in a 73-year-old man with idiopathic CD4+ T lymphocytopenia. Mycoses (1996) 0.99
CD4+CD7- leukemic T cells from patients with Sézary syndrome are protected from galectin-1-triggered T cell death. Leukemia (2002) 0.98
Colorado family physicians' knowledge of hereditary breast cancer and related practice. J Cancer Educ (2001) 0.98
Familial juvenile onset psoriasis is associated with the human leukocyte antigen (HLA) class I side of the extended haplotype Cw6-B57-DRB1*0701-DQA1*0201-DQB1*0303: a population- and family-based study. J Invest Dermatol (1996) 0.98
Wild-type operator binding and altered cooperativity for inducer binding of lac repressor dimer mutant R3. J Biol Chem (1994) 0.97
Demonstration of frequent occurrence of clonal T cells in the peripheral blood of patients with primary cutaneous T-cell lymphoma. Blood (1997) 0.97
Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer (2000) 0.95
Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol (1999) 0.95
Transfection into mouse L cells of genes encoding two serologically and functionally distinct bovine class I MHC molecules from a MHC-homozygous animal: evidence for a second class I locus in cattle. Immunology (1990) 0.95
In vivo methods for the analysis of the penetration of topically applied substances in and through the skin barrier. Int J Cosmet Sci (2012) 0.94
Green fluorescent protein variants fold differentially in prokaryotic and eukaryotic cells. J Cell Biochem Suppl (2001) 0.94
Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. J Eur Acad Dermatol Venereol (2010) 0.94
Biochemical and immunological characterization of the human carcinoma-associated antigen MH 99/KS 1/4. Int J Cancer (1993) 0.93
Common pathogenetic pathways in allergic and irritant contact dermatitis. J Invest Dermatol (1992) 0.93
Subclinical activation of latent cytomegalovirus (CMV) infection and anti-CMV immune response in patients with atopic dermatitis. Br J Dermatol (2003) 0.93
The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res (2009) 0.93
Expression of the B7/BB1 activation antigen and its ligand CD28 in T-cell-mediated skin diseases. J Invest Dermatol (1994) 0.93
Association between interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and early and late-onset psoriasis. Br J Dermatol (1997) 0.93
Cloning of murine IL-22 receptor alpha 2 and comparison with its human counterpart. Genes Immun (2004) 0.92
Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer (1995) 0.92
Viral warts in organ transplant recipients: new aspects in therapy. Br J Dermatol (2003) 0.91
In vitro generation of mast cell-like cells from human peripheral mononuclear phagocytes. Int Arch Allergy Appl Immunol (1983) 0.90
Investigation of follicular penetration of topically applied substances. Skin Pharmacol Appl Skin Physiol (2001) 0.90
SIL-TAL1 deletion in T-cell acute lymphoblastic leukemia. Leukemia (1993) 0.90